You are here: Industry Insights > Emergent BioSolutions

News List

Updates for the Janssen and AstraZeneca Vaccines Cross-contamination Lin Zhang
July 13, 2021
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that causes COVID-19 pandemic has spread to over 220 countries and territories around the world as of July 2021.
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement contractpharma
January 14, 2022
Emergent BioSolutions Inc. announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April 1, 2022.
Emergent BioSolutions Signs Agreement with AstraZeneca contractpharma
August 04, 2020
Emergent BioSolutions Inc. has signed an agreement to provide contract development and manufacturing (CDMO) services for large-scale commercial drug substance manufacturing for AstraZeneca’s COVID-19 vaccine candidate, AZD1222.
Emergent BioSolutions and partners to develop Covid-19 therapy pharmaceutical-technology
July 10, 2020
Emergent BioSolutions has partnered with the Mount Sinai Health System and ImmunoTek Bio Centers for the development, manufacture and clinical testing of its Covid-19 hyperimmune globulin candidate, COVID-HIG.
Emergent to produce drug substance for J&Js Covid-19 vaccine pharmaceutical-technology
July 07, 2020
Emergent BioSolutions has entered a five-year agreement with Johnson & Johnson unit Janssen Pharmaceutical for large-scale manufacturing of drug substance for the latter’s Covid-19 vaccine candidate, Ad26.COV2-S.
Emergent BioSolutions Enters Viral Vector and Gene Therapy Arena contractpharma
June 19, 2020
Invests $75mn in Canton site, advanced therapy CDMO drug substance manufacturing services expected to be available beginning in 2023.
J&J selects Emergent BioSolutions for Covid-19 vaccine manufacturing pharmaceutical-technology
April 26, 2020
Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has signed an agreement with Emergent BioSolutions for manufacturing services for its lead investigational Covid-19 vaccine candidate.
J&J strikes deal with Emergent BioSolutions on coronavirus vaccine manufacturing expresspharma
April 24, 2020
Under the deal, valued at about $135 million, Emergent said it would provide drug substance manufacturing services and was reserving large-scale manufacturing capacity.
Emergent Signs $14.5M COVID-19 BARDA Deal contractpharma
April 10, 2020
Partners with U.S. government for comprehensive response to expedite development of plasma-derived therapy for COVID-19.
Emergent Signs Manufacturing Agreement with Novavax contractpharma
April 06, 2020
Emergent BioSolutions has entered an agreement with Novavax to provide molecule-to-market contract development and manufacturing services to produce Novavax’s NanoFlu.

Previous page 1 2 3 Next page